Unknown

Dataset Information

0

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.


ABSTRACT: The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and strategies to overcome resistance are poorly understood. Here we describe two patients with IDH1 R132C-mutated metastatic cholangiocarcinoma who developed acquired resistance to ivosidenib. After disease progression, one patient developed an oncogenic IDH2 mutation, and the second patient acquired a secondary IDH1 D279N mutation. To characterize the putative IDH1 resistance mutation, cells expressing the double-mutant were generated. In vitro, IDH1 R132H/D279N produces (R)-2HG less efficiently than IDH1 R132H. However, its binding to ivosidenib is impaired and it retains the ability to produce (R)-2HG and promote cellular transformation in the presence of ivosidenib. The irreversible mutant IDH1 inhibitor LY3410738 binds and blocks (R)-2HG production and cellular transformation by IDH1 R132H/D279N. These resistance mechanisms suggest that IDH1-mutated cholangiocarcinomas remain dependent on (R)-2HG even after prolonged ivosidenib treatment. Sequential mutant IDH inhibitor therapy should be explored as a strategy to overcome acquired resistance to mutant IDH inhibitors.

SUBMITTER: Cleary JM 

PROVIDER: S-EPMC9440204 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.

Cleary James M JM   Rouaisnel Betty B   Daina Antoine A   Raghavan Srivatsan S   Roller Lauren A LA   Huffman Brandon M BM   Singh Harshabad H   Wen Patrick Y PY   Bardeesy Nabeel N   Zoete Vincent V   Wolpin Brian M BM   Losman Julie-Aurore JA  

NPJ precision oncology 20220902 1


The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and strategies to overcome resistance are poorly understood. Here we describe two patients with IDH1 R132C-mutated metastatic cholangiocarcinoma who developed acquired resistance to ivosidenib. After disease progression, one patient developed an oncogenic IDH2 mutation, and the second patient acquired a secondary IDH1 D279N mutatio  ...[more]

Similar Datasets

| S-EPMC2820383 | biostudies-literature
| S-EPMC3883450 | biostudies-literature
| S-EPMC10516216 | biostudies-literature
| S-EPMC5015873 | biostudies-literature
| S-EPMC11043204 | biostudies-literature
| S-EPMC7934945 | biostudies-literature
| S-EPMC3897211 | biostudies-other
| S-EPMC3100313 | biostudies-literature
| S-EPMC8175383 | biostudies-literature
| S-EPMC7300411 | biostudies-literature